The European Commission on Friday extended the authorization of the Imvanex mpox vaccine to teenagers aged 12 to 17.

With more than 200 mpox-related deaths reported globally, the EMA has approved Imvanex for adolescents aged 12-17 years.

LONDON (Reuters) -Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in ...

The global vaccine alliance Gavi says it will buy 500,000 doses of vaccine against mpox to fight outbreaks of the disease in ...

The global vaccine group Gavi has ordered 500,000 mpox vaccine doses from the German-Danish company Bavarian Nordic. The UN ...

Lessons learned from the COVID pandemic have left the world in a much better position to tackle the current mpox epidemic ...

The World Health Organization says it has granted its first authorization for use of a vaccine against mpox in adults, ...

The Gavi vaccine alliance announced Wednesday a deal with Danish drugmaker Bavarian Nordic to secure 500,000 jabs against ...

The European Medicines Agency (EMA) has approved the use of Bavarian Nordic’s mpox vaccine in adolescents, increasing the ...

Gavi, the Vaccine Alliance and the U.K. government ordered a combined 650,000 doses of Bavarian Nordic’s Jynneos mpox vaccine ...

The rate of mpox infection in the vaccinated group was 0.09 for every 1,000 person-days as compared to 0.20 in the ...

LONDON, Sept 19 (Reuters) - The EU's drug regulator has approved Bavarian Nordic's (BAVA.CO), opens new tab mpox vaccine for ...